Remission and eular good response in 2125 patients with rheumatoid arthritis (RA) receiving TNF-blocking agents and disease-modifying antirheumatic drugs (Dmards):: Results from a longitudinal observational study.

被引：0
|
作者：
Kvien, TK
Mikkelsen, K
Nordvåg, BY
Kaufmann, C
Rodevand, E
Schrumpf, M
Mowinckel, P
机构：
[1] Diakonhjemmet Hosp, Oslo, Norway
[2] Lillehammer Hosp Rheumat Dis, Lillehammer, Norway
[3] Univ Hosp No Norway, Tromso, Norway
[4] Buskerud Cent Hosp, Drammen, Norway
[5] St Olav Hosp, Trondheim, Norway
来源：
ARTHRITIS AND RHEUMATISM | 2004年 / 50卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S394 / S394
页数：1
相关论文
共 50 条
  • [41] Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission after Six Months of Non-tumor Necrosis Factor Biological Disease-Modifying Antirheumatic Drugs (DMARDs) Treatment
    Miwa, Yusuke
    Saito, Mayu
    Furuya, Hidekazu
    Yanai, Ryo
    Ikari, Yuzo
    Hayashi, Tomoki
    Kasama, Tsuyoshi
    Toyoshima, Yoichi
    Inagaki, Katsunori
    INTERNAL MEDICINE, 2017, 56 (17) : 2271 - 2275
  • [42] Safety and patient-reported outcomes through 2 years of treatment with abatacept in rheumatoid arthritis patients receiving background disease-modifying antirheumatic drugs (DMARDs): The ASSURE trial.
    Weinblatt, M. E.
    Combe, B.
    Birbara, C.
    Covucci, A.
    Li, T.
    Becker, J-C
    Aranda, R.
    Keystone, E.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S248 - S249
  • [43] Comparison of Hand-Wrist Findings of Rheumatoid Arthritis Patients According to the Use of Synthetic and Biological Disease-Modifying Antirheumatic Drugs (DMARDs): A Clinical, Radiographic, and Ultrasonographic Study
    Cinar, Cigdem
    Dogan, Yunus Emre
    Harman, Halil
    Yurttutmus, Zeynep
    Bagatir, Nazire
    Doran, Muhsin
    Ones, Kadriye
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (10)
  • [44] Long-term application of disease modifying antirheumatic drugs (DMARD). A single-center, observational study of 1681 patients with rheumatoid arthritis (RA)
    M. Keysser
    G. Keyßer
    C. Keysser
    Zeitschrift für Rheumatologie, 1999, 58 : 267 - 276
  • [45] Reasons and risk factors for discontinuation of treatment with any biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: A long-term observational study
    Terabe, Kenya
    Takahashi, Nobunori
    Asai, Shuji
    Hirano, Yuji
    Kanayama, Yasuhide
    Yabe, Yuichiro
    Oguchi, Takeshi
    Fujibayashi, Takayoshi
    Ishikawa, Hisato
    Hanabayashi, Masahiro
    Hattori, Yosuke
    Suzuki, Mochihito
    Kishimoto, Kenji
    Ohashi, Yoshifumi
    Imaizumi, Takahiro
    Imagama, Shiro
    Kojima, Toshihisa
    MODERN RHEUMATOLOGY, 2023, 33 (05) : 891 - 898
  • [46] Long-term application of disease modifying antirheumatic drugs (DMARD). A single-center, observational study of 1681 patients with rheumatoid arthritis (RA)
    Keysser, M
    Keysser, G
    Keysser, C
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 1999, 58 (05): : 267 - 276
  • [47] Establishment and verification of a nomogram and a preliminary study on predicting the clinical response of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in rheumatoid arthritis patients
    Sun, Zhijian
    Wang, Feiying
    Chen, Jie
    Liu, Xinlei
    Sun, Jiao
    Sui, Yameng
    Zhang, Xiaojie
    Shu, Qiang
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (24)
  • [48] Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial
    Matthijs S. van der Leeuw
    Paco M. J. Welsing
    Maria J. H. de Hair
    Johannes W. G. Jacobs
    Anne C. A. Marijnissen
    Suzanne P. Linn-Rasker
    Faouzia Fodili
    Reinhard Bos
    Janneke Tekstra
    Jacob M. van Laar
    Trials, 21
  • [49] Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial
    van der Leeuw, Matthijs S.
    Welsing, Paco M. J.
    de Hair, Maria J. H.
    Jacobs, Johannes W. G.
    Marijnissen, Anne C. A.
    Linn-Rasker, Suzanne P.
    Fodili, Faouzia
    Bos, Reinhard
    Tekstra, Janneke
    van Laar, Jacob M.
    TRIALS, 2020, 21 (01)
  • [50] Paradigm guiding to tapering or discontinuation of biologic and targeted synthetic disease-modifying antirheumatic drugs in the treatment of patients with rheumatoid arthritis: Results from a local prospective study
    Kaban, Nedim
    Harman, Halil
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2023, 26 (04) : 689 - 698
12345